Responding to Non-Responders
What are our options for DME patients who respond sub-optimally to anti-VEGF therapy – and what is the evidence base for each of those approaches?
Catharina Busch | | Longer Read
At a Glance
- There are no strict guidelines for dealing with DME patients who don’t respond to anti-VEGF injections
- Available options include continuing with the same treatment, switching to another anti-VEGF agent, or switching to a dexamethasone implant
- A recent real-world study shows better outcomes in patients who switched to a dexamethasone implant, compared with patients who were given further anti-VEGF injections.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.